• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1256514 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type5 A4 p, d6 M6 y" R* q* E" Y
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
4 \1 B. @$ s- v+ Author Affiliations
3 r. j2 D0 y, I9 |$ \& T  g. j) s$ X" B- \( U' d0 z
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
! S2 `- S) a8 r7 p1 V) _& q, k2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
/ D. _- F/ _2 F2 y) n3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
+ A( d8 K& k7 k- D0 m4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
. N& ?6 [! s5 M' U$ f5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 3 m$ _8 X8 a3 L$ B7 v" }$ h7 h  e
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan , R" ?! X! Q& p
7Kinki University School of Medicine, Osaka 589-8511, Japan 8 d; t: t: ]9 p
8Izumi Municipal Hospital, Osaka 594-0071, Japan   k# D+ p+ v9 C, k) g) m
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
& ^: ?! m2 L( T, ~2 X& j$ vCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 5 Q* t2 O( i5 `" S
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. : V  P  V+ U8 k$ p4 @: [# |  l" \7 ~

6 r$ T7 `" C6 j7 m0 m& O7 _3 Z
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type . ?* c/ f* @9 T
% `9 C  V" u2 v$ c5 A
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato * u7 L" H( a: e2 V8 W% t

' F* `% o% Z% e3 eAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
: Q6 a3 J- z; n' p- V8 N- B" }" O% X
Published online on: Thursday, December 1, 2011 - F- \- R5 l# h) p- F
! Z% t7 S" {+ m
Doi: 10.3892/ol.2011.507   I) p% {4 Y$ ]$ C4 S" a

; {- }2 @. q8 j! @& {5 nPages: 405-410 7 Q/ D5 L# Y( k6 ^: ^
. f9 ~$ r1 I& _# y$ C2 h6 A( Y
Abstract:
: T( f! d" m$ v: G/ ~S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.' I3 p; K% ^2 N% x) |% n2 n

* |) P$ c2 L0 J7 h# v
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
( p/ g5 @, i0 x4 kF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 8 @2 L% O1 h+ S  j( B
+ Author Affiliations( J9 a6 N. L/ U) N
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu & y7 h2 `; J, J9 I
2Department of Thoracic Surgery, Kyoto University, Kyoto ! v6 r5 v8 @& k  R; v- Q
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
# |7 m: a& b0 K( A' w&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
1 c+ U, K2 n/ p+ @4 N0 kReceived September 3, 2010.
: g) L/ f- i# mRevision received November 11, 2010.
' s& ~3 W: |* R* k8 l2 }Accepted November 17, 2010. 4 l" t: p1 c* @# ?( r* _
Abstract! T7 u, |( D7 I) ^$ g
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed. & j; F+ h+ z% _) B# E
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
1 m$ c, ]; p$ g* X( eResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. 5 K) E. x& H% h' X2 ~
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. % e+ X0 r* k' s2 \% s
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。: N: `: G- t9 k
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?8 q, y+ n- G- t4 s: f8 h/ j7 B
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy  C, O' S# u1 A3 t6 N
http://clinicaltrials.gov/ct2/show/NCT01523587
+ M9 R2 c5 z+ t9 [9 R/ ?2 h' p* `: I( U7 A/ z" Q9 j
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC. q$ r' P2 m) v0 T- N4 \) X
http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
6 d) J8 {0 i: V  R
: |+ ]! M9 v, F9 D2 J; y从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
; B: T" {2 _9 q/ Y( m9 m. ^3 \至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
5 F1 }3 x5 B; d* F* T; ?. M; T从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。: j" ^8 g1 a# e. E+ ~$ }8 a
至今为止,未出 ...
5 `/ W) ]+ W) ^) r) f, F5 e
没有副作用是第一追求,效果显著是第二追求。  `, u7 T7 K$ d" E& K0 B2 {) O
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表